Bermon Stéphane, Vilain Eric, Fénichel Patrick, Ritzén Martin
Laboratoire Motricité Humaine, Education, Sport, Santé (S.B.), Nice Sophia Antipolis University, 06107 Nice, France; Monaco Institute of Sports Medicine and Surgery (S.B.), 98000 Monaco; Department of Human Genetics and Unité Centre National de la Recherche Scientifique Unité Mixte Internationale 3663 "Epigenetics, Data, Politics" (E.V.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095-7088; Department of Reproductive Endocrinology (P.F.), and INSERM Unité 1065, Hôpital l'Archet, University Hospital of Nice, 06200 Nice, France; and Department of Women's and Children's Health (M.R.), Karolinska Institutet and University Hospital, SE-141 86 Stockholm, Sweden.
J Clin Endocrinol Metab. 2015 Mar;100(3):828-30. doi: 10.1210/jc.2014-3603. Epub 2015 Jan 14.
The recent implementation by some major sports-governing bodies of policies governing eligibility of females with hyperandrogenism to compete in women's sports has raised a lot of attention and is still a controversial issue. This short article addresses two main subjects of controversy: the existing scientific basis supporting performance enhancing of high blood T levels in elite female athletes, and the ethical rationale and considerations about these policies. Given the recently published data about both innate and acquired hyperandrogenic conditions and their prevalence in elite female sports, we claim that the high level of androgens are per se performance enhancing. Regulating women with clinical and biological hyperandrogenism is an invitation to criticism because biological parameters of sex are not neatly divided into only two categories in the real world. It is, however, the responsibility of the sports-governing bodies to do their best to guarantee a level playing field to all athletes. In order not cloud the discussions about the policies on hyperandrogenism in sports, issues of sports eligibility and therapeutic options should always be considered and explained separately, even if they may overlap. Finally, some proposals for refining the existing policies are made in the present article.
最近一些主要体育管理机构实施了关于高雄激素血症女性参加女子体育比赛资格的政策,这引起了广泛关注,并且仍然是一个有争议的问题。这篇短文讨论了两个主要争议主题:支持精英女性运动员高血睾酮水平提高运动成绩的现有科学依据,以及关于这些政策的伦理依据和考量。鉴于最近发表的关于先天性和后天性高雄激素血症状况及其在精英女子体育项目中的患病率的数据,我们认为高水平雄激素本身就能提高运动成绩。对患有临床和生物学高雄激素血症的女性进行管理容易招致批评,因为在现实世界中,性别生物学参数并非简单地分为两类。然而,体育管理机构有责任尽力为所有运动员确保公平的竞争环境。为了不使关于体育高雄激素血症政策的讨论变得模糊,即使体育资格问题和治疗选择可能重叠,也应始终分别考虑和解释它们。最后,本文提出了一些完善现有政策的建议。